Review Article
Neoadjuvant Therapy in Differentiated Thyroid Cancer
Table 2
Responses to neoadjuvant chemotherapy in differentiated thyroid cancer.
| | Author and year | Sample size | Intervention | Response |
| | Besic et al., 2012 [11] | 29 with T3 or T4 follicular or Hurthle cell thyroid cancer. | Vinblastine, vinblastine with doxorubicin, or other regimens. | RR 44.8%. | | Besic et al., 2013 [12] | 16 with T3 or T4 papillary thyroid cancer. | Vinblastine, vinblastine with doxorubicin, or other regimens. | RR 40%. | | Ito et al., 2012 [13] | 2 with papillary thyroid cancer with a squamous cell carcinoma component. | Paclitaxel 80 mg/m2. | 50% PR, 50% SD. |
|
|
Definitions: PR: partial response, RR: response rate, defined as decrease in tumor size by >50%, and SD: stable disease.
|
